Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 Receptor Agonist, Semaglutide injection
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
~7 days
Route
SubQ, Oral
Category
GLP-1 / Weight Loss Agonists
Studies
50 references
Key Benefits
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
Mechanism of Action
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut in response to food. It acts on GLP-1 receptors in the pancreas (increasing insulin secretion), brain (reducing appetite and food cravings), stomach (slowing gastric emptying), and liver (reducing glucose production). Its 7-amino-acid modification and fatty acid attachment gives it a half-life of ~7 days, enabling once-weekly dosing.
Dosing Protocols
Standard Weight Management Titration (Wegovy)
- Dose
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- Frequency
- Once weekly, subcutaneous
- Timing
- Same day each week; any time of day
- Cycle
- 16–20 weeks titration; ongoing maintenance
Start at 0.25 mg/week for 4 weeks. Increase dose every 4 weeks per titration schedule. Target maintenance dose 2.4 mg/week (Wegovy). Slower titration reduces GI side effects. Should be combined with reduced-calorie diet and exercise.
Diabetes Management (Ozempic)
- Dose
- 0.5 mg → 1 mg → 2 mg
- Frequency
- Once weekly, subcutaneous
- Timing
- Same day each week; any time
- Cycle
- Ongoing per physician guidance
FDA-approved doses for T2DM: 0.5 mg, 1 mg, 2 mg weekly. Titrate per physician guidance and glucose response.
Calculate your draw volume
Enter your vial size and BAC water to get exact injection volumes
Side Effects
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- Fatigue
- Reduced appetite (desired effect, but can be excessive)
- Possible muscle loss if protein intake insufficient
- Rare: pancreatitis, gallbladder disease
Contraindications
Personal or family history of medullary thyroid cancer or MEN2 syndrome (black box warning). Pregnancy or breastfeeding. Severe GI disease. History of pancreatitis — use with caution.
Storage
Store pre-filled pens in refrigerator (2–8°C). Once in use, can store at room temperature (up to 30°C) for up to 56 days. Do not freeze.
Featured In Stacks
Advanced Metabolic Fat Loss Stack
A multi-mechanism fat loss protocol combining GLP-1 agonism, targeted adipose lipolysis, AMPK activation, and mitochondrial biogenesis. Designed for significant, sustained fat loss with metabolic health improvements.
Comprehensive Type 2 Diabetes & Metabolic Syndrome Stack
A multi-mechanism peptide protocol addressing the root causes of type 2 diabetes and metabolic syndrome: insulin resistance, visceral adiposity, hepatic glucose production, beta-cell dysfunction, and chronic metabolic inflammation.
GLP-1 Comprehensive Obesity & Metabolic Reset
Structured GLP-1 agonist protocol for significant weight loss using dose escalation from Semaglutide to Tirzepatide or Retatrutide. Combines gut hormone axis modulation with metabolic enhancers.
Insulin Resistance & Metabolic Syndrome Reversal Protocol
Comprehensive metabolic peptide protocol targeting insulin resistance, visceral adiposity, mitochondrial dysfunction, and chronic inflammation underlying metabolic syndrome.
Clinical Research
- 1.Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting
Nauck MA, Punov V, Kang YM, Lim S · Diabetes, obesity & metabolism · 2026PubMed Verified
- 2.Plasma Proteomic Analysis of APOE ε4 Homozygotes Identifies Preclinical Alzheimer's Disease Alterations Potentially Treatable with Semaglutide
Dammer EB, Afshar S, Bian S, Global Neurodegeneration Proteomics Consortium (GNPC), Levey AI, Fortea J et al. · medRxiv : the preprint server for health sciences · 2026PubMed Verified
- 3.Secondary Prevention of Cardiovascular Events in Patients with Overweight/Obesity in Routine Clinical Practice
Guo W, Wang M, Shin J, Li F, O'Brien EC, Glover L et al. · medRxiv : the preprint server for health sciences · 2026PubMed Verified
- 4.Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity
Correra A, Mauriello A, Cetoretta V, Maratea AC, Riegler L, Di Sarno I et al. · Pharmaceuticals (Basel, Switzerland) · 2026ReviewPubMed Verified
- 5.D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice
Rakhat Y, Banno S, Zhantleu D, Tsunekawa S, Yabe D, Seino Y et al. · Nutrients · 2026PubMed Verified
- 6.A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass
Moscucci F, Baratta F, Pastori D, Menichelli D, Mattioli AV, Gallina S et al. · Nutrients · 2026ReviewPubMed Verified
- 7.Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study
Yugueros A, D'Marco L, Valero A, Vivó E, Martínez-Mas A, Calvé M et al. · Medicina (Kaunas, Lithuania) · 2026PubMed Verified
- 8.Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'
Wang CY · Diabetes, obesity & metabolism · 2026PubMed Verified
- 9.Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
Guo M, Chen S, Dong H, Cai M, Guo M, Cheng H · Naunyn-Schmiedeberg's archives of pharmacology · 2026PubMed Verified
- 10.Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey CJ, Flatt PR, Conlon JM · Peptides · 2026ReviewPubMed Verified
- 11.GLP-1 receptor agonist-associated eosinophilic duodenitis presenting as a bowel obstruction : a case report and literature review
Davidts S, Loumaye A, Dano H, Annet L, Delire B · Acta gastro-enterologica Belgica · 2026Case ReportPubMed Verified
- 12.Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Behers BJ, Sanchez C, Hozayen O, Hozayen Y, Kammer R, Corrigan WT et al. · Journal of cardiovascular development and disease · 2026ReviewPubMed Verified
- 13.Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS
Vafeidou K, Koufakis T, Stavropoulos K, Zarfeiadou M, Doumas M, Patoulias D · Expert review of endocrinology & metabolism · 2026PubMed Verified
- 14.Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023
Adekunle OA, Le P, Boyer C, Gasoyan H, Gupta DY, Tran HT et al. · Obesity (Silver Spring, Md.) · 2026PubMed Verified
- 15.Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study
Hsu HY, Shi HY · Diabetes research and clinical practice · 2026PubMed Verified
- 16.Significant improvement of postural orthostatic tachycardia syndrome (POTS) with semaglutide: a case report
Blitshteyn S, Suresh S, Lorenzi LM · Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026PubMed Verified
- 17.Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System
Seijas-Amigo J, Salgado-Barreira Á, Rodriguez-Penas D, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Mañero M et al. · International journal of clinical pharmacy · 2026PubMed Verified
- 18.Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis
Yang Y, Cheng X, Chen S, Xie J, Chen G, Li L et al. · International journal of surgery (London, England) · 2026PubMed Verified
- 19.Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights
Li L, Jin L, Wang J · International journal of general medicine · 2026PubMed Verified
- 20.Simulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study
Burry E, Plumacker F, Villain N, Amaral S, Damier P, Delrieu J et al. · Revue neurologique · 2026PubMed Verified
- 21.Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis
Momeni P, Laverghetta G, Ligatti J, Li L · Online journal of public health informatics · 2026PubMed Verified
- 22.From Venom-to-Vial-to-Pill: The Translational Journey of GLP-1 Peptides and the Evolving Landscape of Biopharmaceutics Modeling
Madny MA, Murthy A · Journal of peptide science : an official publication of the European Peptide Society · 2026ReviewPubMed Verified
- 23.Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management
Feraco A, Camajani E, Muscogiuri G, Barrea L, Colao A, Caprio M · Current obesity reports · 2026ReviewPubMed Verified
- 24.Weight regain after bariatric surgery: A framework for management
Niedbala CG · JAAPA : official journal of the American Academy of Physician Assistants · 2026ReviewPubMed Verified
- 25.Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study
Kapan A, Brandl T, Waldhör T, Moser O, Felsinger R · Diabetes, obesity & metabolism · 2026PubMed Verified
- 26.Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation
Xu Y, Huang T, Zhang Y, Ji D, Tuttle KR, Carrero JJ et al. · Circulation · 2026PubMed Verified
- 27.Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series
Wong M, Wu A, Garhe PK, Biermann M · Obesity (Silver Spring, Md.) · 2026PubMed Verified
- 28.Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery
Villelabeitia IK, Cohen R, le Roux CW · Heart (British Cardiac Society) · 2026ReviewPubMed Verified
- 29.The use of semaglutide as an add-on therapy in patients with LADA
Lunati ME, Cimino V, Bernasconi D, Romano C, Disoteo O, Rossi A et al. · The Journal of clinical endocrinology and metabolism · 2026PubMed Verified
- 30.Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes
Almukhadeb E, Nagshabandi KN, Alshehri N, Alosaimi K, Almusa HA, Almudimeegh A · International journal of dermatology · 2026ReviewPubMed Verified
- 31.Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial
Rayner B, Mahaffey KW, Mann JFE, Pratley RE, Rossing P, Belmar N et al. · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026PubMed Verified
- 32.Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report
Lo SC Sr, Yeh HJ Sr · Cureus · 2026Case ReportPubMed Verified
- 33.Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide
Duan Z, Wei K, Xue Z, Zhou J, Yang S, Ma S et al. · AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024PubMed Verified
- 34.Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study
Pampanelli S, Terzoni S, Pantanetti P, Di Loreto C, Mazzieri A, Cangelosi G et al. · Diabetes, obesity & metabolism · 2026PubMed Verified
- 35.Semaglutide attenuates autistic-like behaviors in BTBR mice through the shaping of gut microbiota
Liu J, Liu T, Nie L, Zhou L, Luo J, Guo L et al. · Pharmacological research · 2026PubMed Verified
- 36.Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison
Hitaka K, Sugawara T, Matsumoto M, Nio Y · International journal of obesity (2005) · 2026PubMed Verified
- 37.Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis
Zufry H, Hariyanto TI · Obesity research & clinical practice · 2026PubMed Verified
- 38.Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes
Nicolau J, Dotres K, Blanco-Anesto J · Medicina clinica · 2026PubMed Verified
- 39.Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment
Tentolouris A, Koufakis T, Fousteris E · Current obesity reports · 2026ReviewPubMed Verified
- 40.The role of Race and Ethnicity in the response to MASLD treatment: A Review
Laurence A, Gandhi SM, Nylen ES, Sen S · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026ReviewPubMed Verified
- 41.Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity
Færch K, Gomes MM, Bramming M, Sørensen MR, Strathe A · Advances in therapy · 2026PubMed Verified
- 42.Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?
Katzman J, Alpert Z, Kennedy M, Rozell J, Schwarzkopf R, Lajam C · Archives of orthopaedic and trauma surgery · 2026PubMed Verified
- 43.Proteomic Profiling of GLP-1-Mediated Cardioprotection in a Large Animal Model of Chronic Coronary Artery Disease
Zheng C, Stone C, Muir K, Harris D, Sellke FW · Medical research archives · 2025PubMed Verified
- 44.The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis
Hertzer LA, Siegel RM, Kharofa RY, Stackpole KM, Mahabee-Gittens EM · Childhood obesity (Print) · 2026Meta-AnalysisPubMed Verified
- 45.Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis
Wu Y, Wang Z, Tuersun A, Yu Q, Zhong Y, Ali SSA et al. · BMC medicine · 2026PubMed Verified
- 46.Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist
Van Laren J, Friesleben C, Gershovich O, Helm L, Patel RJ, Delate T · Diabetes, obesity & metabolism · 2026PubMed Verified
- 47.Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network
Monzo L, Savarese G, Duarte K, Baudry G, Petrie MC, Girerd N · ESC heart failure · 2026PubMed Verified
- 48.Established and emerging pharmacologic options and unmet need in HFpEF and HFmrEF
Sauer AJ, Ter Maaten JM, Savarese G · ESC heart failure · 2026PubMed Verified
- 49.Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao Y, Zhou F, Mao T, Gao L · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026ReviewPubMed Verified
- 50.A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management
Chen Q, Chen T, Lin W, Chen X · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026PubMed Verified
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.
Was this page helpful?
Launching soon
Build and track your protocol in Staqk
Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.